Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6002020 | 1.00 | CYP1A2 (0.66) | CYP1A2KDM4ELMNAAGTR1MEN1 | |
| SCHEMBL6943916 | 0.90 | LMNA (0.59) | CYP1A2KDM4ELMNAAGTR1MEN1 | |
| SCHEMBL26326254 | 0.88 | CYP1A2 (0.81) | CYP1A2KDM4ELMNAAGTR1MEN1 | |
| SCHEMBL14181121 | 0.83 | LMNA (0.52) | CYP1A2KDM4ELMNAAGTR1MEN1 | |
| SCHEMBL13922493 | 0.83 | GAA (0.52) | CYP1A2KDM4ELMNAAGTR1MEN1 | |
| SCHEMBL4741420 | 0.83 | ALOX15 (0.63) | CYP1A2KDM4ELMNAAGTR1MEN1 | |
| SCHEMBL28498576 | 0.82 | GAA (0.59) | CYP1A2KDM4ELMNAAGTR1GAA | |
| Guaifenesin SCHEMBL4322 | 0.79 | CYP1A2 (1.00) | CYP1A2KDM4ELMNAAGTR1MEN1 | |
| SCHEMBL5827090 | 0.79 | CYP1A2 (0.64) | CYP1A2KDM4ELMNAAGTR1MEN1 | |
| SCHEMBL6481560 | 0.79 | MEN1 (0.64) | CYP1A2KDM4ELMNAAGTR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106569297-A | Polarizing plate | 住友化学株式会社 | 2017-04-19 | — | — | CN | disclosed |
| CN-106569296-A | Polarizing plate | 住友化学株式会社 | 2017-04-19 | — | — | CN | disclosed |
| US-20060167282-A1 | Process for industrially producing optically active 1,4- benzodioxane derivative | KANEKA CORPORATION (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1553095-A1 | PROCESS FOR INDUSTRIALLY PRODUCING OPTICALLY ACTIVE 1,4-BENZODIOXANE DERIVATIVE | KANEKA CORPORATION (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-6573265-B2 | Preventing or treating diseases caused by free radicals of the cellular oxygen metabolism, stimulating nerve cell growth, antagonizing glutamate receptors and/or stimulating the growth notably of glutamergic nerve cells; anticarcinogenic agents; | PHAFAG AKTIENGESELLSCHAFT (LI) | 2003-06-03 | — | — | US | disclosed |
| EP-0841334-B1 | PROCESS FOR PRODUCING 1,4-BENZODIOXANE DERIVATIVES | DAISO CO LTD (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-20010006966-A1 | Use of 1- (aminoalkyl) -3-quinoxaline-2-on derivatives for the preparation of compounds having an antioxidant action | PHAFAG AKTIENGESELLSCHAFT (LI) | 2001-07-05 | — | — | US | disclosed |
| US-5780650-A | Process for preparation of 1,4-benzodioxane derivative | DAISO CO., LTD. (JP) | 1998-07-14 | — | — | US | disclosed |
| EP-0841334-A1 | PROCESS FOR PRODUCING 1,4-BENZODIOXANE DERIVATIVES | DAISO CO., LTD. (JP) | 1998-05-13 | — | — | EP | disclosed |
| US-5212316-A | Respiratory system disorders | BOEHRINGER MANNHEIM ITALIA (IT) | 1993-05-18 | — | — | US | disclosed |
| EP-0303227-B1 | ETHERS AND THIOETHERS HAVING THERAPEUTICAL ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1992-02-05 | — | — | EP | disclosed |
| US-4968706-A | MUCOLYTIC, ANTITUSSIVE, BRONCHODILATOR, ANTIINFLAMMATORY | BOEHRINGER MANNHEIN ITALIA, S.P.A. (IT) | 1990-11-06 | — | — | US | disclosed |
| EP-0303227-A1 | Ethers and thioethers having therapeutical activity, their preparation and pharmaceutical compositions containing them | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010006966-A1 | Use of 1- (aminoalkyl) -3-quinoxaline-2-on derivatives for the preparation of compounds having an antioxidant action | GLS, GLUL, GLS2 | CYP1A2 2150/4885KDM4E 2307/4885LMNA 4220/4885 |
| US-20060167282-A1 | Process for industrially producing optically active 1,4- benzodioxane derivative | STS, CYP1B1, SULT1A1 | CYP1A2 99/4885KDM4E 1398/4885LMNA 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.